By Aaron Bry The FDA fully approved Biogen Inc.’s Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. “Alzheimer’s disease is a brain disease that leads to cognitive decline, impacting more than six million Americans,” said the Alzheimer’s Association. Most patients begin showing signs in their mid-60s, but it can be earlier. The treatment from Biogen […]
The post FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline first appeared on The Florida Star | The Georgia Star.
